Activation of brain prostanoid EP3 receptors via arachidonic acid cascade during behavioral suppression induced by Δ 8-tetrahydrocannabinol

Journal of Neurochemistry

Volumn 88, Issue 1, 2004, Pages 148-154

  Yamaguchi, Taku ^a,b   Kubota, Takashi ^a   Watanabe, Shigenori ^a   Yamamoto, Tsuneyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cannabinoid; Cyclooxygenase; Lever pressing behavior; Prostaglandin E 2; Prostanoid EP3 receptor; Tetrahydrocannabinol

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ARACHIDONIC ACID; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; DELTA8 TETRAHYDROCANNABINOL; DICLOFENAC; DRONABINOL; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; PROSTANOID EP3 RECEPTOR; PROSTANOID RECEPTOR; RECEPTOR SUBTYPE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BRAIN CORTEX; BRAIN TISSUE; CONTROLLED STUDY; HIPPOCAMPUS; ISOMERISM; MALE; MESENCEPHALON; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TASK PERFORMANCE;

ANIMALIA;

EID: 0347363609     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.02151.x     Document Type: Article

References (38)

1. 2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice. Brain Res. 966, 47-53.
2. Audette C. A., Burstein S. H., Doyle S. A. and Hunter S. A. (1991) G-protein mediation of cannabinoid-induced phospholipase activation. Pharmacol. Biochem. Behav. 40, 559-563.
3. 9-Tetrahydrocannabinol increases brain prostaglandins in the rat. Psychopharmacology (Berl.) 90, 499-502.
4. Breder C. D., Dewitt D. and Kraig R. P. (1995) Characterization of inducible cyclooxygenase in rat brain. J. Comp. Neurol. 355, 296-315.
5. Burstein S., Budrow J., Debatis M., Hunter S. A. and Subramanian A. (1994) Phospholipase participation in cannabinoid-induced release of free arachidonic acid. Biochem. Pharmacol. 48, 1253-1264.
6. Caggiano A. O. and Kraig R. P. (1999) Prostaglandin E receptor subtypes in cultured rat microglia and their role in reducing lipopolysaccharide-induced interleukin-1beta production. J. Neurochem. 72, 565-575.
7. 9-tetrahydrocannabinol. J. Neurosci. 18, 5322-5332.
8. Crooke S. T. (1992) Therapeutic applications of oligonucleotides. Annu. Rev. Pharmacol. Toxicol. 32, 329-376.
9. 3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103, 9-15.
10. Dubois R. N., Abramson S. B., Crofford L., Gupta R. A., Simon L. S., Van De Putte L. B. and Lipsky P. E. (1998) Cyclooxygenase in biology and disease. FASEB J. 12, 1063-1073.
11. Fenton W. S., Hibbeln J. and Knable M. (2000) Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol. Psychiatry 47, 8-21.
12. Gardner E. L. and Vorel S. R. (1998) Cannabinoid transmission and reward-related events. Neurobiol. Dis. 5, 502-533.
13. 3H]dopa in various regions of the brain. J. Neurochem. 13, 655-669.
14. Herkenham M., Lynn A. B., Little M. D., Johnson M. R., Melvin L. S., de Costa B. R. and Rice K. C. (1990) Cannabinoid receptor localization in brain. Proc. Natl Acad. Sci. USA 87, 1932-1936.
15. Howlett A. C., Johnson M. R., Melvin L. S. and Milne G. M. (1988) Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol. Pharmacol. 33, 297-302.
16. Hunter S. A. and Burstein S. H. (1997) Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis. Life Sci. 60, 1563-1573.
17. -tetrahydrocannabinol. Prostaglandins Leukot. Essent. Fatty Acids 43, 185-190.
18. Johns A. (2001) Psychiatric effects of cannabis. Br. J. Psychiatry 178, 116-122.
19. Leweke F. M., Giuffrida A., Wurster U., Emrich H. M. and Piomelli D. (1999) Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10, 1665-1669.
20. Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C. and Bonner T. I. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564.
21. 9-tetrahydrocannabinol on delayed matching-to-sample performance in rats. Neurosci. Lett. 201, 139-142.
22. Nakamura K., Kaneko T., Yamashita Y., Hasegawa H., Katoh H. and Negishi M. (2000) Immunohistochemical localization of prostaglandin EP3 receptor in the rat nervous system. J. Comp. Neurol. 421, 543-569.
23. Narumiya S., Sugimoto Y. and Ushikubi F. (1999) Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 79, 1193-1226.
24. 2 induces thermal hyperalgesia in rats: the possible involvement of EP3 receptors. Brain Res. 663, 287-292.
25. Ono N., Saito R., Abiru T., Kamiya H. and Furukawa T. (1986) Possible involvement of prostaglandins in cataleptic behavior in rats. Pharmacol. Biochem. Behav. 25, 463-467.
26. Paxinos G. and Watson C. (1989) The Rat Brain in Stereotaxic Coordinates. Academic Press, Australia.
27. Poddubiuk Z. M. (1976) A comparison of the central actions of prostaglandins A1, E1, E2, Flalpha, and F2alpha in the rat. 1. Behavioral, antinociceptive and anticonvulsant actions of intraventricular prostaglandins in the rat. Psychopharmacology (Berl.) 50, 89-94.
28. Perez-Reyes M., Burstein S. H., White W. R., McDonald S. A. and Hicks R. E. (1991) Antagonism of marihuana effects by indomethacin in humans. Life Sci. 48, 507-515.
29. 9-Tetrahydrocannabinol increases arachidonic acid levels in guinea pig cerebral cortex slices. Mol. Pharmacol. 34, 823-828.
30. Shivachar A. C., Martin B. R. and Ellis E. F. (1996) Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methyl-1H-pyrazole-3-carboximide hydrochloride]. Biochem. Pharmacol. 51, 669-676.
31. Sugimoto Y., Shigemoto R., Namba T., Negishi M., Mizuno N., Narumiya S. and Ichikawa A. (1994) Distribution of the messenger RNA for the prostaglandin E receptor subtype EP3 in the mouse nervous system. Neuroscience 62, 919-928.
32. Ujike H., Takaki M., Nakata K., Tanaka Y., Takeda T., Kodama M., Fujiwara Y., Sakai A. and Kuroda S. (2002) CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol. Psychiatry 7, 515-518.
33. Ushikubi F., Segi E., Sugimoto Y. et al. (1998) Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 395, 281-284.
34. Wartmann M., Campbell D., Subramanian A., Burstein S. H. and Davis R. J. (1995) The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide. FEBS Lett. 359, 133-136.
35. Yamaguchi T., Hagiwara Y., Tanaka H., Sugiura T., Waku K., Shoyama Y., Watanabe S. and Yamamoto T. (2001a) Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice. Brain Res. 909, 121-126.
36. Yamaguchi T., Shoyama Y., Watanabe S. and Yamamoto T. (2001b) Behavioural suppression induced by cannabinoids is due to activation of the arachidonic acid cascade in rats. Brain Res. 889, 149-154.
37. Yamamoto T. and Takada K. (2000) Role of cannabinoid receptor in the brain as its relates to drug reward. Jpn. J. Pharmacol. 84, 229-236.
38. Zhao J., Araki N. and Nishimoto S. K. (1995) Quantitation of matrix Gla protein mRNA by competitive polymerase chain reaction using glyceraldehyde-3-phosphate dehydrogenase as an internal control. Gene 155, 159-165.